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Introduction
Aminoglycosides (AGs) are a class of  antibiotic used to treat life-threatening bacterial infections, including 
tuberculosis, urinary or respiratory tract infections, and sepsis (1) as well as suspected or confirmed bacterial 
infections in neonates (2). Cisplatin is a platinum-based cytotoxic agent used in the treatment of  various sol-
id cancers (3). Two unfortunate side effects of  both classes of  compound are nephrotoxicity and ototoxicity. 
While kidney damage can usually be prevented or reversed (4), damage to the hair cells of  the inner ear is 
permanent (5, 6). AG treatment generates some degree of  hearing loss in about 20% of  patients (7), whereas 
in the case of  cisplatin, permanent hearing loss has been reported in up to 100% of  treated patients (8).
Although the use of  AGs in most developed countries is limited to life-threatening infections where 
it is important to utilize their rapid bactericidal effect, in other parts of  the world they are widely used to 
treat less severe infections, mainly due to their stability at ambient temperature and low cost (9). Cisplatin 
has been used in cancer treatment since 1978, and, despite the side effects and recent introduction of  more 
targeted therapies, it is still a mainstay of  cancer therapy (10). Developing methods to prevent the hearing 
loss associated with these two drug classes is of  considerable importance.
Both compounds damage the sensory hair cells in the cochlea and vestibular end organs of  the 
inner ear (11). In the cochlea, the outer hair cells (OHCs) are most susceptible, more so than the inner 
hair cells (IHCs). OHC death starts at the basal high-frequency end and progresses toward the cochlear 
apex, where lower frequencies are encoded, with higher doses and longer treatment. Both compounds 
can also cause direct or indirect damage to other cell types, including those in the inner ear, again par-
ticularly at higher dosages and with prolonged treatment (11). In the case of  the AGs, hair cell entry is 
predominantly via the mechanoelectrical transducer (MET) channels located at the tips of  the stereo-
cilia (12–14). The MET channels effectively act as 1-way valves, trapping the AGs inside the cells, with 
the rapid accumulation of  the AGs then triggering a chain of  events resulting in hair cell death (15–22). 
Aminoglycoside (AG) antibiotics are widely used to prevent life-threatening infections, and 
cisplatin is used in the treatment of various cancers, but both are ototoxic and result in loss of 
sensory hair cells from the inner ear. ORC-13661 is a new drug that was derived from PROTO-1, 
a compound first identified as protective in a large-scale screen utilizing hair cells in the lateral 
line organs of zebrafish larvae. Here, we demonstrate, in zebrafish larvae and in mouse cochlear 
cultures, that ORC-13661 provides robust protection of hair cells against both ototoxins, the 
AGs and cisplatin. ORC-13661 also prevents both hearing loss in a dose-dependent manner in 
rats treated with amikacin and the loading of neomycin-Texas Red into lateral line hair cells. In 
addition, patch-clamp recordings in mouse cochlear cultures reveal that ORC-13661 is a high-
affinity permeant blocker of the mechanoelectrical transducer (MET) channel in outer hair cells, 
suggesting that it may reduce the toxicity of AGs by directly competing for entry at the level of the 
MET channel and of cisplatin by a MET-dependent mechanism. ORC-13661 is therefore a promising 
and versatile protectant that reversibly blocks the hair cell MET channel and operates across 
multiple species and toxins.
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A slower secondary route of  entry via endocytosis has been identified (23, 24). Various lines of  evi-
dence have also implicated the MET channel in cisplatin ototoxicity (25–27), but a direct interaction 
between cisplatin and mammalian MET channels has not been reported, and it is as yet unclear wheth-
er cisplatin enters the hair cells directly via this route.
A potential strategy to protect hearing is to identify a competitive blocker of  the MET channel that 
would prevent the uptake of  the AGs, and possibly cisplatin, into hair cells (28). Studies on MET channel 
blockers, such as d-tubocurarine, berbamine, and benzamil, have shown that these compounds can protect 
mammalian and/or zebrafish hair cells from AG-induced cell death (28–30). The exact molecular structure 
and composition of  the MET channel is still under debate, and so it is currently difficult to specifically 
design effective compounds. There is, however, considerable evidence indicating that the transmembrane 
channel-like (TMC) family proteins either form or at least contribute to the structure of  the MET channel 
pore (31–37).
Another potential method to prevent hearing loss resulting from AG and cisplatin treatment is to 
reduce the intracellular accumulation of  reactive oxygen species in order to prevent or reduce the induction 
of  apoptosis (38, 39). Despite extensive research and various compounds entering clinical trials, there are 
currently no FDA-approved drugs that protect against cisplatin- or AG-induced hearing loss (40, 41).
An effective way to identify novel protective compounds is the use of  large-scale screening (30, 39, 
42–45). To this end, zebrafish have emerged as an efficient animal model with which to search for protec-
tive compounds (46). Their lateral line organs contain hair cells that are morphologically similar to those in 
the mammalian inner ear and are damaged by the same ototoxic drugs (47, 48). Furthermore, the external 
position on the head and flank of  hair cells and the high fecundity of  the fish make the lateral line system 
a convenient platform for screening large numbers of  compounds over short time frames. PROTO-1 was 
discovered in a small-molecule screen designed to yield drug-like compounds that provide robust protection 
of  lateral line hair cells exposed to AG antibiotics (49, 50). An extensive medicinal chemistry program 
yielded over 400 new compounds that had varying efficacy and physiochemical, pharmacokinetic, and 
toxicological properties (51). One such compound, ORC-13661, was found to have outstanding properties 
and to protect hearing in mature rats in vivo (51). The aims of  the studies presented here were to explore 
the versatility and mechanisms of  protection of  this compound as well as to determine whether it provides 
protection against both AGs and cisplatin in zebrafish lateral line hair cells and in hair cells of  organotyp-
ic mouse cochlear cultures. Furthermore, we examined whether the protection that ORC-13661 provides 
against amikacin-induced hearing loss in rats is dose dependent and whether ORC-13661 itself  directly 
influences hearing in vivo.
Results
ORC-13661 protects zebrafish hair cells from multiple AGs. To assess whether ORC-13661 can protect against 
the damage caused by different AGs, zebrafish larvae (5–7 days after fertilization [dpf]) were exposed for 
24 hours to either gentamicin (1–200 μM) or amikacin (100–1500 μM), or for 1 hour to neomycin (50–200 
μM), in the absence or presence of  varying concentrations of  ORC-13661. Previous experiments have 
shown that the dose-response function for neomycin exposure does not differ between 1- and 24-hour expo-
sure (50). These dose ranges of  the AGs with or without ORC-13661 did not kill any of  the fish, and all 
appeared healthy when observing their swimming behavior. All 3 AGs caused a reliable dose-dependent 
loss of  lateral line hair cells (Figure 1A), although the sensitivity of  the hair cells to the 3 AGs differed 
dramatically. This was exemplified by the concentrations causing 50% loss of  hair cells (LD50). The LD50 
values for gentamicin, neomycin, and amikacin were 10 μM, 67 μM, and 453 μM, respectively.
An increase in hair cell survival was apparent with increasing doses of  ORC-13661 for all 3 AGs 
(Figure 1B). However, the concentration of  ORC-13661 at which 50% of  hair cells survive (HC50) was 
different for each AG. To determine the HC50, we used the lowest concentration of  AG that resulted 
in the death of  approximately 80% of  the hair cells: 50 μM for gentamicin, 200 μM for neomycin, and 
1000 μM for amikacin; we varied the concentration of  ORC-13661. The HC50 was 1.64 μM for gentami-
cin, 0.19 μM for neomycin, and 0.22 μM for amikacin. At the highest concentration used in zebrafish 
(≥8.0 μM), ORC-13661 caused a small but significant loss of  hair cells in the absence of  any ototoxin 
(average of  10% across experiments; P < 0.01, Supplemental Table 1; supplemental material avail-
able online with this article; https://doi.org/10.1172/jci.insight.126764DS1). Lower concentrations of  
ORC-13661 provided lesser degrees of  protection across AG concentrations (Supplemental Figure 1). 
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It is also noteworthy that, at the highest concentration tested (8.3 μM), ORC-13661 offers protection 
against each AG across the range of  concentrations used. These results demonstrate that ORC-13661 
protects zebrafish lateral line hair cells from damage caused by 3 different AGs, making it likely that it 
can protect against other members of  this class of  antibiotics.
ORC-13661 protects mammalian hair cells from gentamicin in vitro. To determine whether ORC-13661 could 
also protect mammalian hair cells from AG damage, we tested gentamicin, probably the most frequently 
prescribed AG, e.g., for treating, together with a penicillin, suspected bacterial infections in newborns (52). 
Cochlear cultures from P2 mice were maintained in control media for 24 hours and then exposed to 5 μM 
gentamicin for a further 48 hours, killing most OHCs in the basal third of  the cochlea. Following expo-
sure, a mid-apical and a mid-basal region of  interest (ROI) were evaluated, corresponding to the 8.5-kHz 
and 45-kHz positions along the mature mouse cochlea. These regions were chosen to directly compare a 
relatively low-frequency region of  the cochlea that is less affected by AGs with a more susceptible high-fre-
quency region. A significant loss of  OHCs was not detected (P > 0.99) in the apical ROI. In the basal ROI, 
significant hair cell death was reliably seen in the presence of  5 μM gentamicin, relative to that seen in 
cultures maintained in the control media for the entire 72 hours (P < 0.001; Figure 2, A, B, and D). Coincu-
bation with concentrations of  ≥20 μM ORC-13661 offered full protection against hair cell loss (Figure 2, C 
and D). Concentrations of  ≤5 μM ORC-13661 offered no protection and 10 μM offered partial protection 
(Figure 2D). ORC-13661 alone, applied to the cultures for 48 hours (after 24 hours in control medium), 
caused no hair cell loss up to and including a concentration of  40 μM, but a significant loss was observed 
at 50 μM, 2.5 times the fully protective concentration (Supplemental Figure 2). In conclusion, as for the 
zebrafish, ORC-13661 protects cochlear hair cells but causes a degree of  hair cell loss when administered 
by itself  at higher concentrations.
ORC-13661 protects hearing from amikacin in rats in a dose-dependent manner. To assess whether the dose-de-
pendent protection against AGs by ORC-13661 demonstrated in vitro could be observed in vivo, adult rats 
were treated for 10 days with 320 mg/kg/d) amikacin sulfate, with or without daily oral administration of  
3 different doses of  ORC-13661. Amikacin is of  interest because it is used as an alternative to gentamicin 
in case of  bacterial resistance to the latter and also because it is the treatment of  choice for several chronic 
infections, making it particularly suitable for testing the potential of  ORC-13661 for translation to patients, 
as chronic treatment increases the chance of  serious hearing loss (11). Auditory brainstem response (ABR) 
threshold shifts relative to preexposure levels were measured 2 weeks after treatment cessation (Figure 3). 
Amikacin treatment in the absence of  ORC-13661 caused cumulative threshold shifts. As consistently seen 
in similar studies, threshold shifts increase at higher frequencies, reaching approximately 20 dB at 32 kHz 
Figure 1. ORC-13661 protects zebrafish lateral line hair cells from AG toxicity in vivo. Hair cell survival in wild-type 
*AB zebrafish at 5–7 dpf treated with aminoglycosides (AGs). (A) Twenty-four-hour treatment with gentamicin (1–200 
μM) or amikacin (100–1500 μM) or one-hour treatment with neomycin (50–200 μM). (B) Treatment with varying doses 
of ORC-13661 (0.10–8.3 μM) with 50 μM gentamicin, 200 μM neomycin, or 1000 μM amikacin. Counts from controls 
without any ORC-13661 are also shown. Means were calculated from α parvalbumin–positive hair cell counts from 4 
neuromasts/fish (SO1, SO2, O1, and OC1) after treatment, with 9–11 fish/treatment group. Percentages reflect the 
average number of hair cells remaining in treated fish, relative to hair cells remaining in vehicle control fish. Vertical 
arrows in A show LD50 for each of the AGs tested; vertical arrows in B show HC50 for ORC-13661 in the presence of 
AGs. Error bars represent SD. ORC-13661 protects against toxicity from all 3 AGs in a dose-dependent manner.
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by 2 weeks after exposure. The data from rats treated with ORC-13661 reveal a dose-dependent decrease 
in the amikacin-induced threshold shift at 16 and 32 kHz, with little difference at lower frequencies. Statis-
tical analysis revealed a highly significant interaction term and main effect of  frequency (P < 0.001) and a 
marginally significant overall effect of  groups (P = 0.05). Post hoc individual comparisons revealed no sig-
nificant differences between groups at 2, 4, or 8 kHz. At 16 kHz protection by ORC-13661 was significant 
at a dose of  5 mg/kg (P < 0.05), and at 32 kHz both 1 mg/kg and 5 mg/kg yielded significant protection 
by ORC-13661 (P < 0.05 and P < 0.001, respectively). Data from the low-dose ORC-13661 group (0.2 mg/
kg) suggest some potentiation of  amikacin toxicity at 16 and 32 kHz. However, these values are within the 
range of  the data from the amikacin group, and differences fail to reach statistical significance. Importantly, 
previously we reported that 5 mg/(kg.day) treatment with ORC-13661 also provides protection against a 
more intensive amikacin exposure period, one that generates a greater hearing loss, suggesting that the 
dose dependency also extends along the exposure dimension (51). Taken together with the protection seen 
against gentamicin in the mouse cochlear cultures, these findings show that ORC-13661 also protects hear-
ing in mammals from different AG antibiotics.
ORC-13661 protects zebrafish lateral line hair cells from cisplatin. In light of  ORC-13661’s capacity to 
protect against a range of  AGs in zebrafish lateral line hair cells and against gentamicin and amikacin 
in the mammalian hair cells, we assessed whether protection of  lateral line hair cells could be found 
against the chemotherapeutic compound cisplatin. We used doses of  cisplatin ranging from 25 to 200 
Figure 2. ORC-13661 protects mouse outer hair cells from gentamicin damage. (A–C) One-day-old mouse cochlear 
cultures prepared from P2 mice were transferred into low-serum medium (LSM) and grown for an additional 48 hours in 
LSM alone, LSM containing 5 μM gentamicin, or LSM containing 5 μM gentamicin in the presence of 20 μM ORC-13661. 
Hair cell loss was not seen in LSM alone (A) whereas substantial outer hair cell (OHC) loss was seen in the presence of 
5 μM gentamicin (B). Coincubation with 20 μM ORC-13661 offered protection against the gentamicin-induced damage 
(C). I, inner hair cell row; O1, OHC row 1; O2, OHC row 2; O3, OHC row 3. (D) Dose-response relationship for ORC-13661 
protection against 5 μM gentamicin. Concentrations of ORC-13661 ≤5 μM offered no protection, 10 μM offered partial 
protection, and ≥20 μM offered full protection. Results are shown for the basal ROI. OHCs were counted in a 221-μm 
length of the organ of Corti from each cochlea. Number of cochleae used were as follows: control, 12; 5 μM gentamicin, 
14; 5 μM gentamicin + [ORC-13661]: 1 μM, 4; 3 μM, 6; 5 μM, 4; 10 μM, 14; 20 μM, 11; 30 μM, 5. For statistical analysis 
1-way ANOVA was used; ***P ≤ 0.001. Error bars represent SEM. Scale bar: 20 μm.
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μM and doses of  ORC-13661 ranging from 0.10 to 8.33 μM (Figure 4). Cisplatin treatment causes lat-
eral line hair cell loss across all concentrations tested, with an LD50 of  60 μM. As for AGs, ORC-13661 
offers nearly complete protection of  lateral line hair cells at the highest dose tested, and a dose-depen-
dent increase in cell survival at lower doses, across the range of  cisplatin concentrations (P < 0.001). 
The HC50 for protection against 200 μM cisplatin, a dose that kills approximately 80% of  hair cells, 
was 2.2 μM. We conclude that ORC-13661 offers a comparable degree of  protection of  zebrafish hair 
cells against cisplatin, as it does against AGs.
ORC-13661 protects mammalian hair cells from cisplatin. ORC-13661 was also tested to assess its abil-
ity to protect early postnatal mammalian cochlear hair cells from cisplatin. Cochlear cultures from P2 
mice were exposed to 5 μM cisplatin for 48 hours, a dose sufficient to kill OHCs in all but the most 
apical region of  the cochlea. Significant (P < 0.001) hair cell loss occurred in both the mid-apical (data 
not shown) and mid-basal ROIs of  mouse cochlear cultures in the presence of  5 μM cisplatin alone 
(Figure 5, A, B, and D). In the mid-apical ROI, ORC-13661 offered full protection of  mouse OHCs 
at concentrations of  ≥10 μM and partial protection at concentrations of  ≤5 μM (data not shown). In 
the basal ROI protection mirrored that seen against gentamicin, with concentrations of  ≥20 μM ORC-
13661 offering full protection, 10 μM offering partial protection, and ≤5 μM not providing significant 
protection (Figure 5, C and D). ORC-13661, therefore, protected hair cells with comparable efficacy 
against both cisplatin and gentamicin.
ORC-13661 blocks OHC MET currents. We next investigated possible mechanisms by which ORC-13661 
might be protective. To determine whether or not ORC-13661 can interact with the MET channel, a 
known entry route of  the AGs into the mammalian hair cells (12–14), MET currents were recorded from 
P2 OHCs at membrane potentials ranging from –164 mV to +96 mV, before, during, and after superfusion 
of  the cells with varying concentrations of  ORC-13661 (0.01–10 μM). Examples of  the currents recorded 
when using 0.3 μM and 3 μM ORC-13661 are shown in Figure 6, A–C and E–G. At both concentrations 
Figure 3. ORC-13661 prevents hearing threshold shifts in amikacin-treated rats. 
Hearing threshold shifts in rats treated with a 10-day course of amikacin [320 mg/
(kg.day); subcutaneous injection] with or without concurrent ORC-13661 [0.2, 1, 5 mg/
(kg.day); oral administration]. Mean pretreatment to post-treatment shifts in hear-
ing thresholds are reported; positive values indicate increasing levels of hearing loss. 
Amikacin treatment alone results in a substantial loss of hearing between 4 and 32 
kHz; hearing threshold shifts in rats receiving 1 and 5 mg/(kg.day) of ORC-13661 were 
significantly reduced at 32 kHz (P < 0.05 and P < 0.01, respectively) compared with 
amikacin alone. Controls were treated with ORC-13661 or saline alone. The number 
of recordings for each condition was as follows: control, 16; amikacin, 19; ORC-13661 
(0.2 mg/kg) + amikacin, 5; ORC-13661 (1 mg/kg) + amikacin, 8; ORC-13661 (5 mg/kg) 
+ amikacin, 7. Within a condition n numbers are the same for each frequency tested. 
For statistical analysis 2-way ANOVA was used. Error bars represent SEM.
Figure 4. ORC-13661 protects zebrafish lateral line hair cells 
from cisplatin toxicity in vivo. Hair cell (HC) survival in wild-
type *AB zebrafish at 5–7 dpf treated with cisplatin (25–200 
μM) for 24 hours with (0.10–8.33 μM) or without (control) 
ORC-13661. Values were determined by counting the number 
of α parvalbumin–positive HCs in 4 neuromasts/fish after 
treatment, with 9–11 fish/treatment group. Percentages reflect 
the number of HCs remaining in treated fish, relative to HCs 
remaining in vehicle control fish (n = 30–33 per dosage group). 
For statistical analyses 2-way ANOVA was used. Error bars 
represent SD. Results demonstrate that ORC-13661 protects 
against cisplatin toxicity in a dose-dependent manner.
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a reduction in the size of  the currents was seen during ORC-13661 superfusion, which was most pro-
nounced at negative potentials, and with a stronger reduction at the higher concentration of  ORC-13661. 
Currents partially recovered following reexposure of  the cells to the control solution. Current-voltage 
functions derived from the currents in Figure 6, A–C and E–G, further confirm the partial recovery fol-
lowing washout (Figure 6, D and H). These findings establish that ORC-13661 is a reversible blocker of  
the MET channel of  auditory hair cells.
ORC-13661 MET channel block is voltage dependent and permeant. To investigate the nature of  the MET 
channel block, we first plotted average normalized current-voltage relationships for all cells and concentra-
tions examined (Figure 7A). The currents during ORC-13661 superfusion were normalized to the maxi-
mum control currents at +96 mV measured from the same cell. These data demonstrate the voltage depen-
dence of  the block, with greater block at negative potentials. They also clearly demonstrate the increase in 
level of  block with increasing concentration of  ORC-13661.
Fractional block plots, showing the current during ORC-13661 exposure relative to the control cur-
rent, were then generated for each concentration studied (Figure 7B). The level of  the block can be seen 
to increase with increasing hyperpolarization of  the cells. However, at intermediate concentrations (0.1–1 
μM), a release of  the block is clearly evident at hyperpolarized potentials (negative to about –60 mV). This 
release is suggestive of  a permeant blocker, with the positively charged compound dislodged from the chan-
nel and entering the cell due to the strong electrical driving force.
Figure 5. ORC-13661 protects mouse outer hair cells from cisplatin damage. (A–C) Mouse cochlear cultures prepared 
from P2 mice were maintained in vitro for 1 day and then divided into 3 conditions for an additional 48 hours: low-se-
rum medium (LSM) alone, LSM containing 5 μM cisplatin, or LSM containing 5 μM cisplatin in the presence of 20 μM 
ORC-13661. Hair cell loss was not seen in LSM alone (A), and substantial outer hair cell loss was seen in the presence 
of 5 μM cisplatin (B). Coincubation with 20 μM ORC-13661 offered full protection (C). I, inner hair cell row; O1, OHC row 
1; O2, OHC row 2; O3, OHC row 3. (D) Dose-response function of ORC-13661 protection against 5 μM cisplatin. As in the 
gentamicin assay, concentrations of ORC-13661 ≤5 μM offered no protection, 10 μM offered partial protection, and ≥20 
μM offered full protection. Results are shown for the basal region of interest. OHCs were counted in a 221-μm length of 
the organ of Corti from each cochlea. Numbers of cochleae counted were as follows: control 8; 5 μM cisplatin, 8; 5 μM 
cisplatin + [ORC-13661]: 3 μM, 6; 5 μM, 5; 10 μM, 7; 20 μM, 6; 30 μM, 5; 40 μM, 5. For statistical analysis 1-way ANOVA 
was used. Error bars represent SEM. Scale bar: 20 μm.
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Finally, dose-response functions for ORC-13661 block were generated at each membrane potential, 
with the dose-response function derived from the currents measured at –104 mV shown in Figure 7C. These 
functions were fitted with the equation:
  (Equation 1)
where IC is the control current in the absence of  the compound, [B] is the concentration of  the blocking 
compound, KD is the half-blocking concentration, and nH is the Hill coefficient, which determines the steep-
ness of  the concentration dependence of  the block. The half-blocking concentrations and Hill coefficient 
values obtained from each dose-response function are shown in Figure 7D. The KD values did not vary 
greatly between membrane potentials of  –124 and +36 mV, ranging from a minimum of  0.12 μM at –64 
mV to 0.19 μM. These values are an order of  magnitude lower than those previously reported for MET 
channel block by the styryl dye FM1-43 (≥1.2 μM; ref. 53) and the AG dihydrostreptomycin (≥7 μM; ref. 
12), indicating that ORC-13661 is a relatively high-affinity blocker of  the MET channel at these membrane 
potentials. The KD value was approximately doubled at –164 mV (0.35 μM), a potential close to the electri-
cal gradient across the MET channel in vivo, a reflection of  the progressive release of  the block at hyperpo-
larized potentials. Similarly, at the extreme depolarized potentials, the KD can be seen to increase sharply, 
indicating a reduction in the block. The Hill coefficient ranged from 0.26 to 0.59. These values suggest that 
2 molecules of  ORC-13661 interact with each channel pore, showing negative cooperativity (54). A similar 
channel interaction has been reported for the alkaloid d-tubocurarine (29). These results demonstrate that 
ORC-13661 is, similar to the AGs themselves and other positively charged compounds, a permeant blocker 
of  the MET channel (12, 29, 55).
Kinetics of  MET channel block. To investigate the kinetics of  MET channel block by ORC-13661, and 
to address the question of  whether ORC-13661 is an open-channel blocker (requiring the channel to 
open before the compound can access its binding site) or alternatively, a blocker that can reside in the 
closed channel, step stimuli were delivered to the hair bundles via a fluid jet. From a holding potential 
Figure 6. ORC-13661 blocks the hair cell’s mechanoelectrical transducer channel. (A–C and E–G) Mechanoelectrical transducer (MET) currents measured 
from mid-coil outer hair cells in a 2-day-old culture prepared from a P2 mouse before, during, and after extracellular exposure to 0.3 μM (A–C) and 3 μM 
(E–G) ORC-13661. Currents were measured at membrane potentials ranging from –164 to +96 mV. A sinusoidal stimulus delivered to the fluid-jet (shown 
above each trace; driver voltage [DV]) resulted in the opening and closure of the MET channels. Currents are reduced during exposure to ORC-13661, pre-
dominantly at hyperpolarized potentials, and recover partially following reexposure to control solution. (D and H) Current-voltage relations measured from 
the cell exposed to 0.3 μM (D) and 3 μM (H) ORC-13661 before, during, and after ORC-13661 superfusion. These relations further reveal a greater reduction 
in current size at hyperpolarized potentials and partial recovery during washout. Cell capacitances were 8.4 pF (A–C) and 8.0 pF (E–G). Number of cells 
recorded from exposure to 0.3 μM n = 10 and 3 μM n = 5. All experiments were performed at room temperature (20°C–22°C).
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of  –84 mV, excitatory step stimuli resulted in rapidly activating and saturating inward currents that 
showed minimal inactivation during the time course of  the step. Examples of  the currents recorded 
before ORC-13661 application are shown in Figure 8 (black traces). Currents were then recorded during 
extracellular superfusion of  0.3 μM (Figure 8A) or 3 μM (Figure 8B) ORC-13661 (red traces). The 
currents before and during ORC-13661 superfusion were scaled and superimposed to allow for a direct 
comparison between the kinetics. Differences were not observed between the control currents and the 
currents measured during exposure to ORC-13661 at either concentration. This suggests one of  two 
things: that the kinetics of  the block are faster than the mechanical step and therefore too rapid to 
observe or alternatively, that ORC-13661 is not an open-channel blocker and does not require the chan-
nel to open in order to reach its binding site. An open-channel block would result in a decline in the cur-
rent during the time course of  the step as previously reported for the channel blockers d-tubocurarine, 
berbamine, and amiloride and its analogs (29, 56). The lack of  difference in the offset kinetics during 
the inhibitory step again suggests that either the release of  block is faster than the channel closure or 
that ORC-13661 can reside in the closed channel, as has been suggested for FM1-43 (53). Similar obser-
vations were made from all cells examined ([ORC-13661]: 0.3 μM, n = 7; 3 μM, n = 2 OHCs). As it is 
not possible to determine whether or not ORC-13661 is an open-channel blocker, one cannot calculate 
its entry rate through the MET channels into the hair cells (12, 57).
ABR thresholds are unchanged in rats given large doses of  ORC-13661. In light of  the finding that ORC-13661 
acts as a permeant blocker of  the hair cell MET channel in vitro, we sought to determine if  exposure to 
ORC-13661 in vivo would interfere with hearing in mature rats. To determine if  acute exposure would 
Figure 7. ORC-13661 acts as a high-affinity permeant blocker of the mechanoelectrical transducer channel. (A) Average, normalized current-voltage func-
tions for control currents and currents during ORC-13661 exposure (0.01–10 μM) reveal both the increase in block with increasing ORC-13661 concentration 
and the voltage dependence of the block. The block is strongest at hyperpolarized potentials, but some degree of block can also be observed at depolar-
ized potentials. (B) Fractional block plots showing the current during ORC-13661 superfusion relative to the control current at each membrane potential. 
At intermediate concentrations (0.1–1 μM) the block can be seen to increase with increasing hyperpolarization, with a release of the block at extreme 
hyperpolarized potentials, indicative of a permeant blocker. Cell numbers for both A and B are as follows: control, 33; 0.01 μM, 3; 0.03 μM, 4; 0.1 μM, 4; 0.3 
μM, 10; 1 μM, 5; 3 μM, 5; 10 μM, 2. (C) Dose-response function derived from the currents measured at –104 mV, revealing a half-blocking concentration of 
0.14 μM at this membrane potential. Between 2 and 10 cells were used for each data set. (D) Equilibrium dissociation constants (KD) and Hill coefficients 
obtained from dose-response functions derived from the currents measured at each membrane potential. KD values vary between 0.12 and 2.62 μM and 
the Hill coefficient ranges from 0.26 to 0.59.
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interfere, we treated animals with a single dose of  up to 200 mg/kg ORC-13661, a dose up to 40-fold higher 
than the maximum daily therapeutic dose used in the in vivo rat protection studies (5 mg/kg; Figure 3; ref. 
51). Rats were treated by oral gavage with doses of  100 or 200 mg/kg ORC-13661, or an equivalent volume 
of  sterile saline, and then anesthetized with isoflurane. ABR thresholds were determined immediately after 
dosing and after 1 hour, 5 hours and 24 hours. It is important to note that following oral gavage ORC-13661 
in plasma did not reach maximum concentration until 4–6 hours (Oricula Therapeutics, unpublished data). 
The results of  this study are shown in Figure 9. ABR threshold shifts were determined by calculating the 
differences between thresholds measured immediately after oral gavage and those at later times for frequen-
cies from 2–32 kHz at octave intervals. There were no consistent changes in thresholds at any time after 
introduction of  ORC-13661 at any test frequency in any of  the experimental groups. In addition, there 
were no significant differences in thresholds between the experimental groups or in the saline group. To test 
for late effects, a group of  rats was tested 20 days after a single dose of  200 mg/kg ORC-13661; again, no 
threshold shifts were observed.
Additional experiments were conducted to determine if  repeated daily exposure to ORC-13661 would 
interfere with hearing. Rats treated for 12 days by oral gavage at 5 mg/kg show no reliable threshold shifts 
(51). An additional rat that was given 15 mg/kg each day by oral gavage and tested after 16 days and after 
24 days did not show any sign of  a hearing loss at any frequency. These experiments demonstrate that ORC-
13661 treatment in vivo does not cause a significant temporary or long-term change in hearing threshold.
ORC-13661 does not interact with IK,neo. During the first postnatal week OHCs express a voltage-activated 
basolateral potassium current, called IK,neo, that activates at around –50 mV (58). Block of  this current could 
potentially, over time, depolarize the cells and therefore reduce the driving force for the positively charged 
AGs to enter the cells. To investigate whether ORC-13661 could offer protection against AG damage via this 
route, we examined potential interactions between ORC-13661 and IK,neo. Currents were activated by a series 
of  hyperpolarizing and depolarizing voltage steps from a holding potential of  –84 mV. Figure 10A shows 
an example of  the currents recorded before and during exposure to 10 μM ORC-13661. The currents were 
not affected by the presence of  ORC-13661, indicating this compound does not interact with the basolateral 
potassium channels. Normalized and averaged steady-state current voltage relationships from all cells stud-
ied (n = 4) can be seen in Figure 10B. These data further reveal the lack of  interaction between ORC-13661 
and the basolateral potassium channels, thus excluding this as a potential mechanism of  protection.
ORC-13661 blocks uptake of  neomycin-Texas Red in zebrafish hair cells. The observation that ORC-13661 
can interact with the mammalian MET channel raises the possibility that protection against the AGs, 
and potentially cisplatin too, is via a competitive block of  this channel, resulting in reduced drug entry 
through the channel. To further investigate this hypothesis, zebrafish larvae were exposed to 200 μM neo-
mycin-Texas Red (neo-TR) in the absence or presence of  ORC-13661 (24). In the absence of  ORC-13661, 
neo-TR can be visualized inside hair cells within 3 minutes, causing morphological changes by 19 min-
utes. Hair cell death is first observed within 20 minutes (Figure 11, top row, and Supplemental Video 1). 
Figure 8. Kinetics of ORC-13661 block. Mechanoelectrical transducer (MET) currents measured in response to fluid-jet 
step stimuli in the presence and absence of ORC-13661. Saturating excitatory and inhibitory step stimuli (±40 V driver 
voltage shown above each trace; DV) were delivered to mid-coil outer hair cells (OHCs) in a 2-day-old culture prepared 
from a P2 mouse before and during exposure to 0.3 μM (A) and 3 μM (B) ORC-13661 from a holding potential of –84 
mV. Opening of the MET channels resulted in rapidly activating inward currents. Control currents (black traces) and 
currents during ORC-13661 block (red traces) have been superimposed to compare the kinetic information. In all cases, 
minimal current inactivation is observed during the steps, with no differences seen in offset kinetics. Cell capacitanc-
es were 7.1 pF (A) and 8.0 pF (B). Similar results were obtained from all OHCs examined (n = 7 at 0.3 μM; n = 2 at 3 μM). 
Experiments were performed at room temperature (20°C–22°C).
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ORC-13661 (0.10 μM–8.33 μM) was added to the medium simultaneously with neo-TR. When neo-TR 
was applied in the presence of  8.33 μM ORC-13661 loading was not visible and neither morphological 
changes or cell death were observed (Figure 11, bottom row, and Supplemental Video 2). Quantification 
of  the cell body fluorescence reveals a dose-dependent decrease in neo-TR uptake with increasing ORC-
13661 concentration (Figure 12). One-way ANOVA revealed a highly significant linear trend (P < 0.001), 
and the hair cell uptake of  neo-TR was significantly reduced at each concentration of  ORC-13661 (P < 
0.001), compared with the control. The data show that, in zebrafish hair cells, ORC-13661 does compete 
for entry with a fluorescently labeled AG.
Discussion
Protection. Previous screens have identified compounds that can protect both zebrafish lateral line and 
mammalian hair cells from AG damage, including PROTO-1 (the precursor of  ORC-13661), tacrine, 
phenoxybenzamine, berbamine, d-tubocurarine, and various ion channel modulators (29, 44, 49, 59, 60). 
A drug library screen has also identified 2 compounds that protect lateral line hair cells from both AG- 
and cisplatin-induced damage (paroxetine and benzamil; ref. 30). Phenotypic optimization of  PROTO-1, 
a compound found to protect mammalian and lateral line hair cells from acute AG damage but not 
cisplatin (49, 50), led to the synthesis of  ORC-13661 (51). In this study we demonstrate that ORC-13661 
can protect hair cells from multiple species against both AG- and cisplatin-induced toxicity. In the lateral 
line organs of  zebrafish larvae, ORC-13661 was found to protect against a number of  AGs with differ-
ent toxicity profiles and clinical applications, including neomycin, gentamicin, and amikacin. Robust 
protection against both gentamicin and cisplatin was observed with zebrafish in vivo and with neonatal 
Figure 9. High doses of ORC-13661 alone do not affect hearing in rats. Hearing threshold shifts in rats that were 
orally administered ORC-13661 (A, 100 mg/kg; B, 200 mg/kg) or saline (C) are shown. Auditory brainstem response 
(ABR) thresholds were determined immediately after dosing and after intervals of 1 hour, 5 hours, and 24 hours for 
100 mg/kg dosing and 1 hour, 5 hours, 24 hours, and 20 days for 200 mg/kg dosing. n = 3 for each dosage group at 1 
hours, 5 hours, and 24 hours; n = 2 for 20-day group; and n = 2 for saline group. Mean hearing threshold shifts com-
pared with thresholds immediately after treatment are reported ± 1 SEM; positive values indicate increasing levels 
of hearing loss. For statistical analysis 2-way ANOVA was used. No consistent or statistically significant hearing 
threshold shifts were observed in any of the conditions tested.
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mammalian cochlear hair cells in vitro utilizing low (micromolar) concentrations of  ORC-13661. Fur-
thermore, ORC-13661 protected against amikacin-induced hearing loss in rats in vivo. ORC-13661 is 
therefore capable of  alleviating hair cell death across a range of  species and assays as well as a range 
of  ototoxins, including several AGs with different damage profiles and cisplatin, making it an attractive 
compound for further development.
Mechanism. As ORC-13661 protects across species and against a range of  ototoxic compounds that 
have multiple (though likely overlapping) mechanisms of  action as well as potentially different entry 
routes into cells, it is theoretically possible that it may provide protection at multiple levels. In mammals, 
there is clear evidence that AGs act as permeant blockers of  the MET channels, entering but not readily 
leaving through these channels and thereby accumulating inside the cells (12–14). In zebrafish, abolition 
of  MET currents by mutations in cdh23 or myo7a, or using the channel blocker benzamil, prevents entry 
of  fluorescently tagged AGs (24). Blocking these channels could therefore reduce or prevent intracellular 
accumulation of  the AGs. Although zebrafish lateral line hair cells require functional MET channels 
for cisplatin-induced cell death to occur (26), there is currently no evidence that cisplatin actually enters 
lateral line hair cells through the MET channels in this species. The hair cells might instead be less met-
abolically stressed when the MET current is absent, e.g., due to a reduced Ca2+ influx, thus increasing 
their resistance to ototoxic drugs (61). Whether or not the MET channels contribute to entry of  cisplatin 
in mammalian hair cells remains uncertain. Cisplatin has been shown to block MET currents in chick 
cochlear hair cells (25), and a study in guinea pigs concluded that cisplatin, when applied directly into 
scala media via iontophoresis (and therefore charged, i.e., aquated), brought about hearing loss through 
a block of  OHC transduction channels (62). While in the clinic hearing loss due to cisplatin treatment is 
due to hair cell death rather than MET current inhibition (63, 64), these findings do suggest that cisplatin 
ototoxicity is MET dependent in some way, either directly or indirectly. We therefore sought to deter-
mine whether or not ORC-13661 could interact with the MET channel. Whole-cell patch-clamp record-
ings from OHCs revealed that ORC-13661 is a relatively high-affinity permeant blocker of  the MET 
channel, with a half-blocking concentration of  0.14 μM at –104 mV in the presence of  1.3 mM Ca2+. 
The block was rapid and reversible, with the currents recovering following washout of  the compound. 
We also found that ORC-13661 can prevent the loading of  neo-TR in zebrafish hair cells. Together, these 
results are consistent with the hypothesis that protection against AGs can be conferred by a direct com-
petitive block of  the channel, reducing intracellular accumulation, as has been suggested for gentamicin 
with both berbamine and d-tubocurarine (29). In the absence of  direct evidence of  whether or not cispla-
tin can enter mammalian hair cells through the MET channel (65), these data are at least consistent with 
prevention of  MET-dependent toxicity as found in lateral line hair cells (26, 61).
Figure 10. ORC-13661 does not block the basolateral potassium current, IK,neo. (A) Basolateral currents were measured 
from a P2+3 days in vitro mid-coil outer hair cell in response to a series of voltage steps from a holding potential of 
–84 mV, before (left) and during (right) extracellular exposure to 10 μM ORC-13661. A schematic representation of the 
voltage-step protocol is shown below each of the current traces. Similar current sizes can be observed during exposure 
to control solution and 10 μM ORC-13661, revealing a lack of interaction with the channel. Cell capacitance was 6.35 pF. 
(B) Average steady-state current-voltage functions further reveal the lack of interaction between ORC-13661 and the 
basolateral potassium channel (n = 4). Currents were normalized to the steady-state control current at +46 mV for each 
cell. Experiments were performed at room temperature (20°C–22°C).
1 2insight.jci.org   https://doi.org/10.1172/jci.insight.126764
R E S E A R C H  A R T I C L E
While our data support a mechanism of  action where ORC-13661 reduces ototoxicity by blocking 
MET channels, other mechanisms are possible. MET current recordings reveal a clear release of  the block 
by ORC-13661 at hyperpolarized potentials (tested up to –164 mV), most evident at the intermediate con-
centrations of  ORC-13661 (0.1–1 μM). This indicates that the positively charged ORC-13661 can enter 
into the hair cells through the MET channels, being pulled into the cells by the strong electrical gradient. 
Such strong hyperpolarized potentials are physiologically relevant in vivo because they are generated across 
the MET channel by the positive endocochlear potential of  +80 to +100 mV (66) and the negative resting 
potential of  –40 to –60 mV (67). ORC-13661 can also directly cross membranes, as demonstrated by its 
properties in hydrophobicity and membrane permeability assays and reflected by its oral bioavailability 
(51). Although we do not know the relative magnitudes of  entry through the MET channels versus the 
cell membrane, it is clear that ORC-13661 can enter the hair cells and could conceivably protect from AG 
and/or cisplatin damage intracellularly. ORC-13661 could potentially interact with multiple intracellular 
pathways. Recent studies have reported the activation of  distinct but overlapping cell death pathways after 
exposure of  lateral line hair cells to neomycin, gentamicin (50, 68), and cisplatin (69). The fact that ORC-
13661 protects against all of  these suggests that it functions at a common early point. The concentrations of  
ORC-13661 offering 50% protection (HC50) of  zebrafish hair cells vary among the 3 AGs and cisplatin for 
a similar degree of  hair cell death (approximately 80%), with neomycin requiring the least and cisplatin the 
most. This is compatible with the idea that protection is conferred through a block of  the MET channel, as 
differing concentrations of  ORC-13661 may be required to impede the entry of  the different AGs or reduce 
MET-dependent cisplatin toxicity. MET channel interactions and AG entry rates into the hair cells are like-
ly to vary between the AGs, as supported by their differing chemical structures with varying charges and 
charge distributions between the molecules (70). PROTO-1 derivatives that lack a positive charge are not 
expected to interact with the cation-selective MET channel (12), and all such derivatives were uniformly 
inactive in the zebrafish protection assay (51). The available evidence therefore suggests that MET channel 
block by ORC-13661 is the likely mechanism for preventing hair cell death.
We provide evidence that ORC-13661 acts as a permeant blocker of the hair cell MET channel in vitro. 
This raises the question of whether ORC-13661 treatment alone may impair hearing in adult mammals and 
humans. Both pharmacokinetic analysis and empirical experiments suggest not. First, the maximal plasma con-
centration of ORC-13661 at the efficacious dose in rats (5 mg/kg) is 240 nM. However, in plasma 90% is bound 
to protein, meaning the free concentration at this dose is only 24 nM (51). We do not know the concentrations 
of ORC-13661 in perilymph or indeed (directly relevant to MET channel block) the endolymph, but analysis of  
other drugs indicates that concentrations in the cochlear fluids are less than half  of plasma, and in some cases 
far less, with endolymph concentrations lower than perilymph concentrations (71, 72). Therefore, protection of  
hair cells in vivo likely occurs at ORC-13661 concentrations that are at least an order of magnitude below those 
Figure 11. ORC-13661 blocks entry of neomycin-Texas Red into brn3c:gfp zebrafish lateral line hair cell bodies in vivo. 
Time-lapse imaging of lateral line neuromasts of brn3c:gfp-transgenic zebrafish exposed to neomycin-Texas Red (neo-
TR) with and without ORC-13661. Images were captured at 30-second intervals for 50 minutes immediately following 
neo-TR treatment at a concentration of 200 μM. In the top row of images, hair cells show a progressive accumulation of 
intracellular neo-TR (200 μM). Some cells are dying by 20 minutes. In the bottom row of images, hair cells are exposed 
to neo-TR (200 μM) and cotreatment with ORC-13661 (8.33 μM). At this concentration, cotreatment with ORC-13661 
virtually eliminates red fluorescence in hair cell bodies and all cells survive. Times at the top of each panel indicate time 
(minutes) from introduction of neo-TR. Scale bar: 1 μm.
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at which it blocks 50% of the MET channels in vitro in early postnatal mouse cochlear cultures. One possibility 
that we cannot exclude is that ORC-13661 might also conceivably compete with AGs for entry into the endo-
lymph. This would require the development of techniques for reliably sampling fluid from endolymph, which 
is prone to contamination (71). Consistent with this analysis, we used ABRs to monitor hearing in rats up to 24 
hours after doses of ORC-13661 up to 200 mg/kg and did not find any consistent changes in thresholds (Fig-
ure 9) or input/output functions (data not shown). We also found no changes in thresholds after chronic daily 
treatment with ORC-13661 for up to 24 days. Similar findings have been reported for AGs themselves; while 
they are efficient permeant blockers of the MET channel (12), their concentrations in the inner ear are lower 
than in plasma (72), and they usually do not cause acute hearing loss in humans during the time of exposure.
Translation to the clinic. ORC-13661 was selected from over 400 newly synthesized compounds because 
of its high otoprotective efficacy, oral bioavailability, and excellent pharmacokinetic properties; moreover, it 
showed no interference with the antimicrobial efficacy of various AGs (51). The present study adds to the evi-
dence that ORC-13661 protects hearing in rats efficiently following oral administration, is well tolerated, and 
does not itself  affect hearing, even if  administered daily over weeks at higher concentrations than those used 
for otoprotection. The next steps toward taking these findings to the clinic include confirming that these advan-
tageous characteristics also apply to human subjects. Indeed, ORC-13661 has been patented (US 9416141 and 
US 9493482), approved by the FDA for use in human clinical trials, and is currently in phase I trials.
Methods
Zebrafish husbandry and embryo generation
Adult wild-type *AB Danio rerio (zebrafish) and offspring were maintained in the University of  Washington 
zebrafish facility (24). Tg(pou4f3:gap43-GFP)s356tTg zebrafish express GFP fused to a GAP-43 membrane–tar-
geting sequence in hair cells of  the lateral line and inner ear under control of  the pou4f3 (brn3c) promoter 
(73) and are referred to here as brn3c:gfp. Experiments were carried out 5–7 dpf, a time point at which hair 
cells are susceptible to AG toxicity (74, 75). Larval zebrafish were acquired through paired or group mat-
ing and raised at 28.5°C in E2 embryo media (14.97 mM NaCl, 500 μM KCl, 42 μM Na2HPO4, 150 μM 
KH2PO4, 1 mM CaCl2, 1 mM MgSO4, 0.714 mM NaHCO3, pH 7.2) (76). For treatment, fish 5−6 dpf  were 
transferred into 48-well culture plates containing 300 μL embryo medium.
Cochlear culture preparation
Cochlear cultures were prepared from wild-type CD-1 mice (originally obtained from Charles River Lab-
oratories) at P2 as previously described (77). In brief, pups were killed by cervical dislocation (following 
United Kingdom Home Office Guidelines), and heads were sterilized by three 1-minute washes in 80% 
ethanol. Whole cochleae were removed and further dissected in Hanks Balanced Salt Solution (HBSS; 
Gibco by Life Technologies, 14025050) buffered with 10 mM HEPES (MilliporeSigma, H0887) and plated 
on collagen-coated (Corning, 354236) coverslips in cochlear culture medium (93% DMEM-F12, 7% FBS 
and 10 μg/ml ampicillin). Plated cochleae were then sealed into Maximow slide assemblies and incubated 
for 24 hours at 37˚C, 5% CO2, to allow growth and adherence to the collagen.
Figure 12. ORC-13661 cotreatment significantly 
reduces neomycin-Texas Red fluorescence in 
lateral line hair cell bodies. Quantification of 
neomycin-Texas red (neo-TR) fluorescence in the 
hair cell bodies of brn3c:gfp zebrafish cotreated 
with 25 μM neo-TR and ORC-13661 (0.10–8.33 μM) 
for 10 minutes. Each graphed symbol represents 
1 hair cell, with 5–16 hair cells sampled from 2–4 
neuromasts per fish in 2–4 fish per treatment 
group. Average fluorescence relative to baseline 
of hair cell bodies in fish treated with neo-TR 
alone is significantly greater than that observed 
in any group cotreated with ORC-13661 (P < 0.001 
for all groups). For statistical analysis 1-way ANO-
VA was used. Error bars represent SD.
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Reagents
Neomycin solution (10 mg/ml; catalog N1142) and gentamicin solution (50 mg/ml; catalog G1397) were 
purchased from MilliporeSigma. Amikacin was purchased from Medisca (catalog 0295). Cisplatin solution 
was acquired from the University of  Washington Medical Centre pharmacy or from Strides ArcoLab Ltd. 
ORC-13661 was obtained in powdered form from Oricula Therapeutics. The composition and purity of  
ORC-13661 were as previously described (51). For the zebrafish experiments described here, ORC-13661 
was dissolved in embryo medium to the desired concentration the day of  the experiment.
Zebrafish hair cell protection assay
Protection assays were conducted as described in detail previously (43, 51). In brief, 5–7 dpf  zebrafish were 
treated with AG or cisplatin and varying concentrations of  ORC-13661 (0.9–8.3 μM with gentamicin; 0.1–
8.0 μM with amikacin; 0.1–8.3 μM with neomycin and cisplatin; or 8.3 μM ORC-13661 alone in embryo 
media [E2]). Hair cells were fixed and immunohistochemistry was performed with anti-parvalbumin prima-
ry antibody. Neuromasts SO1, SO2, O1, and OC1 (78) were used for hair cell counts in 9–11 fish per group.
Cochlear culture protection assay
After the initial 24-hour growth period, coverslips with adherent cochleae were removed from the slide 
assemblies and placed in 35-mm diameter petri dishes (Greiner Bio-One, 627161) in cochlear culture medi-
um containing a reduced concentration of  FBS (1.4%) in the presence of  5 μM gentamicin (MilliporeSig-
ma, G1397) or 5 μM cisplatin (Strides ArcoLab Ltd.) and varying concentrations of  ORC-13661 (1–40 
μM). After 48-hour incubation cultures were washed once with PBS and fixed at room temperature for 1 
hour in 3.7% formaldehyde (MilliporeSigma, F1635) buffered with 0.1 M sodium phosphate (pH 7.4). Fol-
lowing fixation, cultures were preblocked, permeabilized, and labeled with either 1:1000 TRITC phalloidin 
(MilliporeSigma, P1951) or 1:200 Texas red X phalloidin (Invitrogen, T7471) and 1:1000 anti-myosin-VIIa 
rabbit polyclonal antibody (Proteus, 25-6790) followed by 1:500 Alexa Fluor 488 goat anti-rabbit IgG (Invi-
trogen, A-11034). Cultures were mounted on glass slides in Vectashield (Vector Laboratories, H-1000) and 
imaged using a Zeiss Axioplan2 upright microscope.
Hair cell assessment
Zebrafish. Fish were euthanized after treatment by immersion in the anesthetic MESAB (tricaine; MS-222; 
ethyl m-aminobenzoate methanesulfonate; MilliporeSigma, E10521), followed by fixation with 4% parafor-
maldehyde in 0.1 M PBS (pH 7.4) for 1 hour at room temperature, and blocked in PBS supplemented with 
0.1% Triton X-100 and 5% normal goat serum (MilliporeSigma, S26) for 1–2 hours at 25°C. Samples were 
incubated in 1:400 primary mouse anti-parvalbumin antibody (MilliporeSigma, MAB1572) at 4°C overnight 
and then 1:500 secondary goat anti-mouse antibody conjugated to Alexa Fluor 488 (Thermo Fisher, A-11001) 
or 568 (Thermo Fisher, A-11004) at 4°C overnight, washing with PBS + 0.1% Triton X-100 between all steps. 
Fish were mounted on bridged coverslips and viewed with a Zeiss Axioplan 2ie epifluorescence microscope. 
Hair cell counts were performed in 4 neuromasts per fish (SO1, SO2, O1, and OC1) (75), and counts were 
summed to arrive at 1 value per fish. Hair cell counts were performed for 9–13 fish per treatment. The HC50 
was calculated as a linear interpolation (linear hair cell count and logarithmic concentration axes) from the 
nearest concentrations of  protective drug that produced hair cell survival below and above 50%.
Mouse cochlear cultures. Each concentration of  ORC-13661 was tested on a minimum of  4 cochle-
ar cultures. Images of  labeled hair cells were captured using a ×40 objective (0.75 NA) on a Zeiss 
Axioplan2 microscope from mid-apical and mid-basal regions, at a distance approximately 20% from 
the apical and basal (hook) ends of  the cochlea, respectively, using a Spot RT slider digital camera. 
The corresponding characteristic frequencies of  the mature mouse cochlea at these locations were 
calculated (79) and found to be 8.5 kHz and 45 kHz, respectively. If  the cochlear epithelium was not 
perfectly flat, images were obtained from multiple focal planes and merged using Adobe Photoshop 
Creative Cloud (2017 version) to ensure clear visibility of  all cells present in the region. Numbers of  
OHCs were counted in a 221 μm (1200 pixel) length of  the organ of  Corti. Cells in cultures treated 
with gentamicin were counted based on presence of  hair bundle alone, while those in cisplatin-treat-
ed cultures were counted based on presence of  both a hair bundle and a cell body. Quantification 
of  cisplatin-treated cultures was performed in this manner due to cisplatin-induced damage causing 
approximately 7% of  cells to be decapitated, meaning that the hair bundle was not associated with a 
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cell body. The incidence of  this phenotype in gentamicin-treated cultures is approximately 2% and so 
is not considered sufficiently high to warrant quantifying based on double labeling.
Electrophysiology
MET and basolateral potassium currents were recorded and measured using previously described methods 
(29). In brief, all currents were recorded from OHCs in organotypic cultures prepared from P2 CD-1 mice 
using the whole-cell configuration of  the patch-clamp technique and cultures that had been maintained in 
vitro for 1–2 days. MET currents were recorded in the absence and presence of  ORC-13661 (0.01–10 μM) at 
membrane potentials ranging from –164 mV to +96 mV. Currents were elicited by stimulating the hair bun-
dles using a fluid jet from a pipette (tip diameter 8–10 μm) driven by a piezoelectric disc (12, 80). Mechanical 
stimuli (filtered at 1.0 kHz, 8-pole Bessel) with driver voltage amplitudes of  ±40 V were applied as 45-Hz 
sinusoids. Basolateral currents were recorded in the absence and presence of  10 μM ORC-13661 at membrane 
potentials ranging from –154 to +46 mV. All currents were acquired using pClamp (Molecular Devices) soft-
ware and stored on a computer for offline analysis. During recordings, series resistance compensation was 
applied (70%–80%) with the average residual series resistance calculated to be 1.13 ± 0.07 MΩ (n = 34). MET 
currents reached a maximum size of  1.41 ± 0.10 nA (n = 30), compared with 2.35 ± 0.10 nA (n = 4) for the 
steady-state basolateral potassium currents, resulting in maximum voltage drops across the residual series 
resistance of  1.58 and 2.66 mV, respectively. These values were considered sufficiently small to not require 
any correction to quoted voltage values. All experiments were conducted at room temperature (20°C–22°C).
Time-lapse microscopy of  neo-TR hair cell loading. brn3c:gfp fish were cotreated with neo-TR and ORC-13661 
in E2 media at room temperature. Images of lateral line neuromasts were captured with a Marianas spinning 
disk system (Intelligent Imaging Innovations) following previously described protocols (24). Green fluores-
cence from brn3c:gfp expression was acquired using 490 nm excitation and 535/30 emission; Texas red fluo-
rescence was acquired using 561 nm excitation and 617/73 emission. Images were acquired every 30 seconds.
Neuromasts were imaged in 16-bit depth stacks using a Zeiss LSM 880 Airyscan super-resolution sys-
tem. Image volumes were acquired at 1-μm intervals encompassing the Z-axis of  the neuromast, after 10 
minutes of  incubation in neo-TR with and without ORC-13661, and used to generate maximum intensity 
projections. GFP fluorescence was used as a guide to manually draw ROIs representing individual hair 
cells; the average fluorescence intensity of  each ROI was quantified using the ZenBlue (Zeiss) program.
ABR experiments
ABRs were measured in 40- to 50-day-old male Fischer 344 rats (Harlan Laboratories) prior to drug treatments 
and again at 2 weeks after the termination of drug treatment. In brief, 320 mg/k/d amikacin sulfate USP 
(Medisca) was administered subcutaneously to rats with or without oral ORC-13661 daily for 10 consecutive 
days, and the protective effect of 3 doses of ORC-13661 [0.2, 1, or 5 mg/kg/d] was assessed. Controls included 
ORC-13661 alone [5 mg/kg/day] and saline. ORC-13661 was dissolved in PEG300/DMA/EtOH/H2O (2.0 
mg ORC-13661, dissolved in 0.03 ml DMA, 0.12 mL EtOH, 0.45 ml PEG-300, and 0.4 ml of sterile water to 
obtain a 1-ml solution with a final concentration of 2 mg/ml). ORC-13661 was administered by oral gavage 
within 15 minutes of the amikacin treatment. Controls were gavaged with ORC-13661 alone or saline for 10 
days. All rats survived for 2 weeks after the drug treatment with no further drug exposure.
For ABR recordings, rats were anesthetized with isoflurane, placed on a heating pad to maintain body 
temperature near 38°C, and placed in a double-walled sound-attenuating chamber. ABR responses were 
recorded using standard subcutaneous needle electrodes, with the positive and negative electrodes at the 
left temporal bone above the pinna and the vertex of  the skull and the ground electrode in the thigh. Free-
field pure tone stimuli were generated, and ABR recordings were digitized using custom software. Tone 
pips were 5 millisecond in duration with 1-millisecond rise/fall times, presented at a repetition rate of  19/s. 
In addition, broadband clicks were presented at the beginning and end of  each session to assess for any 
changes in the animal’s condition. All stimuli were calibrated online at the beginning of  each experiment 
with a calibrated probe microphone. Neural responses were preamplified (100×; A-M Systems amplifier 
model 3000), sent through an MA3 amplifier with an additional 20-dB postpreamp gain (Tucker Davis 
Technologies), bandpass filtered (100–3000 Hz; Krohn-Hite filter model 3550), and digitized at 24.4 kHz. 
Responses were sampled in a 15-millisecond window (with a 5-millisecond stimulus onset delay). The 
threshold was defined as the lowest sound pressure level (SPL) in which a recognizable waveform was 
present and repeatable. Thresholds were determined at 2, 4, 8, 16, and 32 kHz and for a broadband click. 
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Stimuli were presented 500 times from 80 to 20 dB SPL in steps of  10 and then 1000 repetitions in steps of  
5 dB SPL when approaching threshold. Near threshold each series was repeated to determine the reliability 
of  the waveform at the estimated threshold, 5 dB above and 10 dB below the estimated threshold. When 
animals appeared to be deaf  at a particular frequency, the stimulus was presented at the maximum intensity 
generated by our system (90–100 dB SPL) at least twice at 1000 repetitions to be assured of  a complete 
hearing loss. The threshold was then arbitrarily set at 100 dB SPL.
All averaged responses were examined online. Following the experimental session, all responses were 
rescored offline twice, once by the experimenter and once by an ABR expert who was blinded with regard 
to the experimental conditions. We used very conservative estimates by only including wave 1 responses, 
ensuring reliability by always repeating stimulus trains 2 or more times near threshold and demanding at 
least wave 1 peak-to-peak amplitudes greater than waveform oscillations prior to stimulus onset. Values of  
thresholds prior to treatments for each experimental group are shown in Supplemental Table 2. Thresh-
old estimates were within 5 dB in over 97% of  the response traces; the few that differed by >10 dB were 
reexamined by the 2 evaluators to come to a consensus. Data were analyzed as raw thresholds at each test 
frequency and as “threshold shift,” comparing the pretest threshold with the threshold after drug adminis-
tration, where a positive number indicates a hearing loss (in dB) due to the drug treatment (51).
Statistics
Zebrafish. GraphPad Prism 6.0, 7.0, or 7.2 was used to carry out 2-tailed t tests (to assess the effects of  8.3 
μM ORC-13661 alone) or 1-way or 2-way ANOVA (for all other comparisons). When significant main 
effects and/or interactions were found appropriate individual comparisons were performed using Sidak, 
Dunnett, or Tukey post hoc testing. For graphical presentation, data were normalized to untreated con-
trols, such that 100% represents hair cell survival in control animals.
Cochlear cultures. GraphPad Prism 7.2 was used to carry out 1-way ANOVA on raw cell counts with 
Sidak post hoc testing. Treatments were classified as fully protective if  they were found to have cell counts 
both significantly different from ototoxin alone and not statistically different from control cell counts; if  sig-
nificantly different from both ototoxin alone and control, the treatment was considered partially protective, 
and if  treatments were significantly different from negative control but not statistically different from the 
ototoxin-alone control, then the treatment was not considered to be protective.
ABR recordings. Statistical analyses were done using GraphPad Prism 7.0. A 2-way mixed ANOVA fol-
lowed by Dunnett’s post tests was used to evaluate differences in threshold shift from pretreatment values 
at 2, 4, 8, 16, and 32 kHz and for a broadband click.
Results were considered significant at P ≤ 0.05, with levels of  statistical significance shown in figures.
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